|
1
|
Casado-Díaz A, Santiago-Mora R, Dorado G
and Quesada-Gómez JM: Risedronate positively affects osteogenic
differentiation of human mesenchymal stromal cells. Arch Med Res.
44:325–334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Crandall C: Risedronate: A clinical
review. Arch Intern Med. 161:353–360. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dunn CJ and Goa KL: Risedronate. A review
of its pharmacological properties and clinical use in resorptive
bone disease. Drugs. 61:685–712. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Välimäki MJ, Farrerons-Minguella J, Halse
J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M and Snorre
Øfjord E: Effects of risedronate 5 mg/d on bone mineral density and
bone turnover markers in late-postmenopausal women with osteopenia:
A multinational, 24-month, randomized, double-blind,
placebo-controlled, parallel-group, phase III trial. Clin Ther.
29:1937–1949. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
D'Amelio P, Grimaldi A, Di Bella S, Tamone
C, Brianza SZ, Ravazzoli MG, Bernabei P, Cristofaro MA, Pescarmona
GP and Isaia G: Risedronate reduces osteoclast precursors and
cytokine production in postmenopausal osteoporotic women. J Bone
Miner Res. 23:373–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jin SH, Lee JE, Yun JH, Kim I, Ko Y and
Park JB: Isolation and characterization of human mesenchymal stem
cells from gingival connective tissue. J Periodontal Res.
50:461–467. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fujita H, Kurokawa K, Ogino T, Ono M,
Yamamoto M, Oka T, Nakanishi T, Kobayashi N, Tanaka N, Ogawa T, et
al: Effect of risedronate on osteoblast differentiation, expression
of receptor activator of NF-κB ligand and apoptosis in mesenchymal
stem cells. Basic Clin Pharmacol Toxicol. 109:78–84. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
White NJ and Perry CM: Risedronate once a
week. Treat Endocrinol. 2:415–420; discussion 421. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Frampton JE: Risedronate on two
consecutive days per month. Drugs Aging. 26:355–362. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dougherty JA: Risedronate for the
prevention and treatment of corticosteroid-induced osteoporosis.
Ann Pharmacother. 36:512–516. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tauchmanovà L, De Simone G, Musella T,
Orio F, Ricci P, Nappi C, Lombardi G, Colao A, Rotoli B and Selleri
C: Effects of various antireabsorptive treatments on bone mineral
density in hypogonadal young women after allogeneic stem cell
transplantation. Bone Marrow Transplant. 37:81–88. 2006.PubMed/NCBI
|
|
12
|
Delmas PD, Benhamou CL, Man Z,
Tlustochowicz W, Matzkin E, Eusebio R, Zanchetta J, Olszynski WP,
Recker RR and McClung MR: Monthly dosing of 75 mg risedronate on 2
consecutive days a month: Efficacy and safety results. Osteoporos
Int. 19:1039–1045. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ogura Y, Gonsho A, Cyong JC and Orimo H:
Clinical trial of risedronate in Japanese volunteers: A study on
the effects of timing of dosing on absorption. J Bone Miner Metab.
22:120–126. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mitchell DY, Barr WH, Eusebio RA, Stevens
KA, Duke FP, Russell DA, Nesbitt JD, Powell JH and Thompson GA:
Risedronate pharmacokinetics and intra- and inter-subject
variability upon single-dose intravenous and oral administration.
Pharm Res. 18:166–170. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peris P, Atkinson EJ, Gössl M, Kane TL,
McCready LK, Lerman A, Khosla S and McGregor UI: Effects of
bisphosphonate treatment on circulating osteogenic endothelial
progenitor cells in postmenopausal women. Mayo Clin Proc. 88:46–55.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang G, Zhu Z, Lei C, Li M, Liu F, Mao Y,
Yu Z, Liu M, Zhao X and Tang T: Low-dose risedronate sodium
protects bone cells after abrupt oestrogen withdrawal. J Int Med
Res. 40:1761–1774. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park JB, Zhang H, Lin CY, Chung CP, Byun
Y, Park YS and Yang VC: Simvastatin maintains osteoblastic
viability while promoting differentiation by partially regulating
the expressions of estrogen receptors α. J Surg Res. 174:278–283.
2012. View Article : Google Scholar : PubMed/NCBI
|
